- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02176317
Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)
December 2, 2019 updated by: Joanne Kurtzberg, MD, Duke University
This study is a prospective phase 1 single-center trial designed to determine the safety of a single intravenous infusion of autologous umbilical cord blood in children with Autism Spectrum Disorder (ASD) and assess the feasibility of various outcome measures to determine which measure(s) can be used as primary and secondary endpoints for a future randomized phase 2 clinical trial.
All subjects will receive infusion of cord blood cells at baseline with follow up assessments at 6 and 12 months.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Autism Spectrum Disorder (ASD) is a neurodevelopment disorder with early onset in life.
Currently, available treatments for patients with ASD are supportive, but not curative.
Umbilical cord blood (UCB) has been shown to lessen the clinical and radiographic impact of hypoxic brain injury and stroke in animal models and in infants with hypoxic ischemic encephalopathy.
UCB also engrafts and differentiates in the brain, facilitating neural cell repair in animal models and human patients with inborn errors of metabolism undergoing allogeneic, unrelated donor UCB transplantation.
Infusion of autologous UCB does not require immunosuppression and has been shown to be safe in young children with brain injuries such as cerebral palsy and stroke.
In this study, the investigators hypothesize that infusion of a patient's own umbilical cord blood cells (UCB) can offer neural protection/repair in the brain and reduction of inflammation associated with this disorder.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 6 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 24 months to ≤72months at the time of visit 1
Confirmed clinical DSM-5 diagnosis of Autism Spectrum Disorder using all three of the following measures:
- Autism Diagnostic Observation Schedule - Toddler or Generic (ADOS)
- Autism Diagnostic Interview-Revised (ADI-R)
- DSM-5 checklist
- IQ ≥ 35 on Stanford Binet Intelligence Scale or similar standardized test
- Autologous umbilical cord blood available from a cord blood bank with a minimum total nucleated cell dose of ≥ 1 x 107 cells/kilogram of subject weight that meets acceptance criteria outlined in section 6.0 with confirmed HLA matching
- Stable on current medications for at least 2 months prior to infusion of cord blood
- Ability to travel to Duke University three times (0, 6, 12 mo.), parent/guardian able to participate in electronic communication tracking two times in the study and interim phone surveys every 3 months
- Parental consent
- Subject and parent/guardian must be English speaking
Exclusion Criteria:
- Unwilling to commit to follow up for a year
- History of prior cell therapy
- Use of IVIG or other anti-inflammatory medications with the exception of NSAIDs
- Medical records indicate that child has genetic or other syndromes such as fragile X, neurofibromatosis, Rett syndrome, tuberous sclerosis, PTEN mutation, cerebral palsy, cystic fibrosis, muscular dystrophy, Crohn's disease, or rheumatoid disease
- Co-morbid condition that would influence child's performance on assessments.
- Central Nervous System (CNS) infection
- History of unstable epilepsy or uncontrolled seizure disorder, infantile spasms, Lennox Gastaut syndrome, Dravet syndrome
- Known pathogenic copy number variation (CNV) (e.g. 16p11.2, 15q13.2, 2q13.3)
- Significant sensory (i.e., deafness, blind) or motor impairment (CP) (if using Language Environment Analysis (LENA), no uncorrected hearing impairment)
- Presence of obvious physical dysmorphology
- Review of medical records indicates ASD diagnosis not likely or other serious complicating genetic or medical condition present
- Impaired renal or liver function as determined by serum creatinine >1.5mg/dL and/or total bilirubin>1.3mg/dL
- Clinically significant abnormalities in Complete Blood Count (CBC): Hemoglobin < 10.0 g/dL, White Blood Count (WBC) < 3.8 x 10e9, Platelets < 150x 10e9.
- Known metabolic disorder, mitochondrial dysfunction
- Uncontrolled infection, presence of or infection with HIV
- Active malignancy
- Macroencephaly or microencephaly ( >2 standard deviations in the relevant direction between head circumference and height)
- Change in current stable use of psychoactive medications; as per parent report.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autologous Umbilical Cord Blood (UCB)
All participants will receive a single intravenous (into the vein) infusion of autologous umbilical cord blood cells.
|
All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10^7 Total Nucleated Cells (TNC)/kilogram of subject body weight.
The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with non-serious and serious adverse events.
Time Frame: up to 12 months
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary efficacy measure will be change in the Vineland Adaptive Behavior Scale- II
Time Frame: up to 12 months
|
up to 12 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Pervasive Developmental Disorder- Behavior Inventory
Time Frame: up to 12 months
|
up to 12 months
|
Change in Repetitive Behavior Scal
Time Frame: up to 12 months
|
up to 12 months
|
Change in Sensory Experience Questionnaire
Time Frame: up to 12 months
|
up to 12 months
|
Change in Behavior Assessment of Children
Time Frame: up to 12 months
|
up to 12 months
|
Change in Autism Diagnostic Observation Scale
Time Frame: up to 12 months
|
up to 12 months
|
Change in Clinical Global Impression- Severity and Improvement Scales
Time Frame: up to 12 months
|
up to 12 months
|
Change in Stanford Binet Intelligence Scale or other standardized IQ test
Time Frame: up to 12 months
|
up to 12 months
|
Change in frequency of child vocalization/ conversational turns
Time Frame: up to 12 months
|
up to 12 months
|
Change in Expressive One-Word Picture Vocabulary Test
Time Frame: up to 12 months
|
up to 12 months
|
Change in Preschool Age Psychiatric Assessment
Time Frame: up to 12 months
|
up to 12 months
|
Change in Aberrant Behavior Checklist
Time Frame: up to 12 months
|
up to 12 months
|
Prevalent and incident of GI symptoms
Time Frame: up to 12 months
|
up to 12 months
|
Change in Parenting Stress Index
Time Frame: up to 12 months
|
up to 12 months
|
Change in attention to social stimuli assessed via eye-tracking and electroencephalography (EEG)
Time Frame: up to 12 months
|
up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2014
Primary Completion (Actual)
December 1, 2015
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
June 16, 2014
First Submitted That Met QC Criteria
June 26, 2014
First Posted (Estimate)
June 27, 2014
Study Record Updates
Last Update Posted (Actual)
December 3, 2019
Last Update Submitted That Met QC Criteria
December 2, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00052449
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hoffmann-La RocheActive, not recruitingAutism Spectrum Disorder (ASD)United States, Canada, Italy, Spain
-
Axial Therapeutics, Inc.Active, not recruitingAutism Spectrum Disorder (ASD)United States, Australia, New Zealand
-
Technion, Israel Institute of TechnologyCompleted
-
Stanford UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAutism | Autism Spectrum Disorder (ASD)United States
-
Corporacion Parc TauliUnknown
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyTerminatedAutism Spectrum Disorder (ASD)Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
-
Florida Gulf Coast UniversityCompletedAutism Spectrum Disorder High-FunctioningUnited States
-
Hospital Universitario Dr. Jose E. GonzalezUnknownAutism | Autism SpectrumMexico
-
National Taiwan University HospitalCompletedAutism Spectrum Disorder High-FunctioningTaiwan
Clinical Trials on Autologous Umbilical Cord Blood
-
MinYoung Kim, M.D.CHA UniversityCompletedGlobal Developmental DelayKorea, Republic of
-
Guangdong Women and Children HospitalRecruitingSafety Issues;Effect of DrugsChina
-
Guangdong Women and Children HospitalUnknownSafety Issues | Effect of DrugsChina
-
The University of Texas Health Science Center,...Texas Medical Center Regenerative Medicine ConsortiumRecruitingCongenital Diaphragmatic HerniaUnited States
-
Michael CottenTerminatedHypoplastic Left Heart SyndromeUnited States
-
Neonatal Encephalopathy Consortium, JapanNational Cerebral and Cardiovascular Center; Nagoya University; Tokyo Women's... and other collaboratorsCompletedNeonatal Encephalopathy | Hypoxic-ischemic EncephalopathyJapan
-
yangjieCompletedSafety Issues | Neonatal Death | BPD - Bronchopulmonary DysplasiaChina
-
Aryn KnightM.D. Anderson Cancer Center; The University of Texas Health Science Center,... and other collaboratorsWithdrawn
-
Guangdong Women and Children HospitalCompletedSafety Issues | Neonatal Death | Effect of Drugs
-
Mononuclear Therapeutics Ltd.Chinese University of Hong Kong; China Spinal Cord Injury NetworkUnknownAnemia, Neonatal | Hypoxic-Ischemic Encephalopathy | Hypoxia Neonatal | Cerebral Ischemia of NewbornHong Kong